UK Markets closed
NIKKEI 225
27,433.40 +50.84 (+0.19%) HANG SENG
22,069.73 -619.17 (-2.73%) CRUDE OIL
77.92 -1.76 (-2.21%) GOLD FUTURES
1,936.80 -8.80 (-0.45%) DOW
33,800.91 -177.17 (-0.52%) BTC-GBP
18,526.16 -813.83 (-4.21%)
BioInvent International AB (publ) (0H22.L)
LSE - LSE Delayed price. Currency in SEK
Add to watchlist
At close: 09:17AM GMT
| Previous close | 45.1750 |
| Open | 45.1800 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 45.1800 - 45.1800 |
| 52-week range | 45.1800 - 45.1800 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.6340 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- ACCESSWIRE
BioInvent Outlines Strong Progress in Clinical and Preclinical Pipeline at R&D Day 2022
BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today provides an update on its clinical and pre-clinical pipeline, including an update on its lead drug candidate, the novel anti-FcγRIIB antibody BI-1206.
- ACCESSWIRE
Invitation to BioInvent’s R&D Day in Stockholm on December 8, 2022
BioInvent International (STO:BINV)
- ACCESSWIRE
BioInvent Receives FDA IND Approval for Anti-FcyRIIB Antibody BI-1607
BioInvent International (STO:BINV)
© 2023 Yahoo. All rights reserved.
